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Abstract 
Background: Sansanmycins are uridyl peptide antibiotics (UPAs), which are inhibitors of translocase I (MraY) and 
block the bacterial cell wall biosynthesis. They have good antibacterial activity against Pseudomonas aeruginosa and 
Mycobacterium tuberculosis strains. The biosynthetic gene cluster of sansanmycins has been characterized and the 
main biosynthetic pathway elucidated according to that of pacidamycins which were catalyzed by nonribosomal 
peptide synthetases (NRPSs). Sananmycin A is the major compound of Streptomyces sp. SS (wild type strain) and it 
bears a non-proteinogenic amino acid, meta-tyrosine (m-Tyr), at the N-terminus of tetrapeptide chain.
Results: ssaX deletion mutant SS/XKO was constructed by the λ-RED mediated PCR targeting method and confirmed 
by PCR and southern blot. The disruption of ssaX completely abolished the production of sansanmycin A. Comple-
mentation in vivo and in vitro could both recover the production of sansanmycin A, and the overexpression of SsaX 
apparently increased the production of sansanmycin A by 20 %. Six new compounds were identified in the fermen-
tation culture of ssaX deletion mutant. Some more novel sansanmycin analogues were obtained by mutasynthesis, 
and totally ten sansanmycin analogues, MX-1 to MX-10, were purified and identified by electrospray ionization mass 
spectrometry (ESI-MS) and nuclear magnetic resonance (NMR). The bioassay of these sansanmycin analogues showed 
that sansanmycin MX-1, MX-2, MX-4, MX-6 and MX-7 exhibited comparable potency to sansanmycin A against M. 
tuberculosis H37Rv, as well as multi-drug-resistant (MDR) and extensive-drug-resistant (XDR) strains. Moreover, sansan-
mycin MX-2 and MX-4 displayed much better stability than sansanmycin A.
Conclusions: We demonstrated that SsaX is responsible for the biosynthesis of m-Tyr in vivo by gene deletion and 
complementation. About twenty novel sansanmycin analogues were obtained by mutasynthesis in ssaX deletion 
mutant SS/XKO and ten of them were purified and structurally identified. Among them, MX-2 and MX-4 showed 
promising anti-MDR and anti-XDR tuberculosis activity and greater stability than sansanmycin A. These results indi-
cated that ssaX deletion mutant SS/XKO was a suitable host to expand the diversity of the N-terminus of UPAs, with 
potential to yield more novel compounds with improved activity and/or other properties.
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Background
Sansanmycins [1], produced by Streptomyces sp. SS, 
belong to the uridyl peptide antibiotics (UPAs) including 
pacidamycins [2], napsamycins [3] and mureidomycins 
[4]. They hold a common and unique structure (Fig.  1), 
a 3′-deoxyuridyl attached to a pseudo-tetra/pentapep-
tidyl backbone via an exocyclic enamide. The pepti-
dyl chain exhibited interesting double reversals due to 
the β-peptidation of the N-methyl-2,3-diaminobutyric 
acid (DABA) and a ureido linkage [5]. Sansanmycins 
exhibit good antibacterial activity against highly refrac-
tory pathogens including Pseudomonas aeruginosa and 
Mycobacterium tuberculosis [6]. With 1.5 million peo-
ple killed by tuberculosis (TB) in 2014, the disease ranks 
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alongside human immunodeficiency virus as a lead-
ing killer worldwide [7]. The increasing emergence of 
multi-drug-resistant (MDR) and extensive-drug-resist-
ant (XDR) tuberculosis make the treatment more diffi-
cult. So there is an urgent need to develop novel anti-TB 
drugs with no cross-resistance to current clinically used 
antibiotics. Sansanmycins and other UPAs are of inter-
est, due that they inhibit a clinically unexploited target 
MraY (phospho-MurNAc-pentapeptide translocase, also 
known as translocase I) [8], which catalyzes the transfer 
of UDPMurNAc-L-Ala-γ-D-Glu-m-DAP-D-Ala-D-Ala 
onto lipid carrier undecaprenyl phosphate to give lipid 
intermediate I in the bacterial peptidoglycan biosynthetic 
pathway. The potential bioactivity against M. tuberculo-
sis coupled to its intriguing structure made this natural 
product a fascinating anti-TB lead compound.
Recently, the biosynthetic gene clusters for pacida-
mycins [5, 9], napsamycins [10], and sansanmycins [11] 
were identified and characterized, indicating that the 
assembly of the pseudo-tetrapeptide chain is catalyzed by 
nonribosomal peptide synthetases (NRPSs) with highly 
dissociated modules [12]. Besides, the biosynthesis of 
uridyl pentapeptide of pacidamycins was catalyzed by 
the tRNA-dependent aminoacyltransferase PacB, which 
transferred the alanyl residue from alanyl-tRNA to the 
N-terminus of the pseudo-tetrapeptide [13]. In contrast 
to ribosomal peptide synthesis, non-ribosomally assem-
bled peptides contain not only the 20 proteinogenic 
amino acids but also many different building blocks, such 
as DABA, D-amino acids, hydroxyl amino acids, N- and 
C-methylated amino acids etc. Among them, non-pro-
teinogenic amino acid meta-tyrosine (m-Tyr) is rarely 
found in bacterial secondary metabolites. UPAs and a 
potent cyclophilin inhibitor sanglifehrin A (SFA) are two 
examples containing m-Tyr as one of the building blocks. 
SfaA, identified in the SFA biosynthetic gene cluster, was 
speculated to catalyze the biosynthesis of m-Tyr [14]. 
As a homologue of SfaA in pacidamycin biosynthetic 
gene cluster, PacX was characterized as a phenylalanine 
3-hydroxylase that catalyzed the synthesis of m-Tyr from 
L-phenylalanine (L-Phe) in  vitro [15]. In sansanmycin 
biosynthetic gene cluster, SsaX is homologous to PacX 
with amino acid identity of 80  % across the whole pro-
tein, indicating that it is responsible for the biosynthesis 
of m-Tyr in Streptomyces sp. SS.
Although natural UPAs have potential to treat refrac-
tory infections, there is no UPAs entering clinical 
trials until now mainly due to their relatively poor phys-
icochemical property. In previous studies, the N-terminal 
amino acid of the tetrapeptide of UPAs was supposed to 
be important functional group for the inhibition of MraY 
[16, 17]. It was proposed that the protonated ammonium 
ion binds in place of the Mg2+ cofactor at the MraY active 
site via cis-amide linkage [17]. The N-terminal amino acid 
of known UPAs is almost dominated by m-Tyr or differ-
ent bicyclic acids (possibly derived from m-Tyr), except 
that some pacidamycins possess Ala instead (Fig.  1). In 
this study, we focus on the substitution of the N-terminal 
amino acid to get novel sansanmycin analogues by muta-
synthesis. Mutasynthesis is a useful method in the gen-
eration of new antibiotic derivatives [18]. This approach 
could expand the chemical diversity of secondary metab-
olites and produce novel compounds with improved 
physicochemical properties or altered bioactivity. For 
example, it has been successfully employed to get novel 
nucleoside antibiotics such as nikkomycin analogues [19] 
and new ansamycin derivatives [20]. However, muta-
tional biosynthesis has not been employed to obtain UPA 
derivatives so far.
Here, we demonstrated that SsaX is responsible for the 
biosynthesis of m-Tyr in vivo by gene deletion and com-
plementation and the sansanmycin production could be 
increased through the overexpression of ssaX. Six new 
Fig. 1 Structures of known uridyl peptide antibiotics
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sansanmycin analogues were purified and characterized 
in ssaX deletion mutant, indicating the substrate flexibil-
ity of the responsible NRPS. To expand the diversity of 
sansanmycins by mutasynthesis, different types of sub-
strates were fed to the ssaX deletion mutant and some 
novel sansanmycin derivatives were obtained. These 
compounds were purified and structurally identified, 
some of which exhibited improved antibacterial activity 
or stability.
Results
In‑frame deletion of ssaX and its complementation
In order to investigate the contribution of ssaX to san-
sanmycin biosynthesis, an ssaX deletion mutant SS/XKO 
was constructed from Streptomyces sp. SS by PCR target-
ing [21] using cosmid 13R-1 [11] which contains ssaX and 
the majority of other biosynthetic genes. Cosmid 13R-1-
SCP2KO was firstly constructed from cosmid 13R-1 with 
the minimal replicon of SCP2* replaced by ampicillin 
resistance gene in order to promote homologous recom-
bination for the disruption of ssaX. Then the ssaX gene 
in 13R-1-SCP2KO was in-frame deleted and the resulted 
13R-1-SCP2KO-XKO was introduced into the wild type 
strain by conjugation (Fig.  2a). The ssaX in-frame dele-
tion mutant SS/XKO was verified by PCR using primers 
PT-X-7 and PT-X-8 (Fig.  2a) and further confirmed by 
southern blot analysis (Fig.  2b, c). The coding region of 
ssaX was cloned into a pSET152 [22] -derived expression 
plasmid, pL646 [23], under the control of a strong con-
stitutive promoter, ermE*p, to give pL-ssaX. The plasmid 
was introduced into SS/XKO strain by conjugation and 
the complementary strain SS/XKO/pL-ssaX was resulted 
to exclude the potential polar effect in SS/XKO. Metabo-
lites of constructed strains were scrutinized to compare 
with that of the wild type strain by HPLC, LC/MS and 
bioassay analysis. The major product in the wild type 
strain, sansanmycin A with m-Tyr at the N-terminus of 
tetrapeptide chain, was not detected in SS/XKO (Fig. 2d). 
The culture broth of SS/XKO showed no antibacte-
rial activity against P. aeruginosa 11, which was used as 
the test microorganism for the bioassay of sansanmy-
cins (Fig. 2e). Meanwhile, the complementary strain SS/
XKO/pL-ssaX completely recovered the production of 
sansanmycin A detected by HPLC analysis (Fig. 2d) and 
antibacterial bioassay (Fig. 2e).
In addition to genetic complementation in  vivo, a 
chemical complementation by feeding the substrate 
m-Tyr (3 mM) to the fermentation medium of the ssaX 
deletion mutant SS/XKO was also performed. The result 
of HPLC showed that the major product of this culture 
broth was sansanmycin A and the production level was 
significantly higher than the wild type strain (Fig.  3a). 
Consistent with this result, the inhibition zone was big-
ger than that of wild type strain in the bioassay (Fig. 3b). 
All of these results demonstrated that SsaX was responsi-
ble for the biosynthesis of m-Tyr in sansanmycin biosyn-
thetic pathway.
To further investigate the role of ssaX in sansanmycin 
biosynthesis, the plasmid pL-ssaX was transferred into 
the wild type strain by conjugation to give the ssaX over-
expression strain SS/pL-ssaX, with pSET152 transferred 
strain SS/pSET152 as a control. With the same growth 
curves, the overexpression of SsaX apparently increased 
the production of sansanmycin A by 20  % from HPLC 
analysis (Fig. 2d). The antibacterial activity against P. aer-
uginosa 11 also showed that SS/pL-ssaX exhibited big-
ger inhibition zone than the control strain (Fig. 2e). This 
result, together with the result of chemical complementa-
tion, suggested that the biosynthesis of m-Tyr catalyzed 
by SsaX is at least one of the rate-limiting steps in the 
sansanmycin production [24].
Isolation and structural determination of sansanmycin 
analogues in ssaX deletion mutant
Through the HPLC and LC/MS analysis, a series of minor 
components of sansanmycin analogues were detected in 
the cultivated broth of ssaX deletion mutant SS/XKO. 
In order to characterize these compounds, SS/XKO fer-
mentations were scaled up to obtain enough amount of 
material for further analysis. The target compounds were 
enriched by macroporous absorbant resin from fermen-
tation broth, then isolated using DEAE-Sephadex A25 
guided by HPLC–UV to yield the crude sansanmycin 
analogues. Subsequently, the crude compounds were 
purified by preparative HPLC. As a result, six new san-
sanmycin analogues were obtained and designated as 
(See figure on next page.) 
Fig. 2 Effects of the deletion of ssaX on sansanmycin production. a Construction of the ssaX deletion mutant (SS/XKO) by PCR targeting and its PCR 
verification (using primers PT-X-7 and PT-X-8). Primers PT-X-1 and PT-X-2 were used to amplify a streptomycin resistance cassette (aadA gene), which 
substituted ssaX on cosmid 13R-1-SCP2KO. bla, ampicillin resistance marker; aac(3)IV, apramycin resistance marker. b, c Southern blot hybridiza-
tion of wild type strain and SS/XKO. The genomic DNAs were digested with BamHI and hybridized with specific probes of ssaX deleted fragment 
(b) and the fragment downstream of ssaX (c) respectively. The wild type strain showed the hybridized band of 4.4 kb both in b and c. The correct 
ssaX deletion mutant showed no hybridized band in b and the hybridized band of 3.7 kb instead of 4.4 kb in c. d HPLC analysis of different strains. 
Sansanmycin A is the major compound in wild type strain with m-Tyr at N-terminus. e Antibacterial activity analysis of different strains. 1, wild type 
strain; 2, SS/XKO; 3, SS/XKO/pL-ssaX; 4, SS/pL-ssaX
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sansanmycin MX-1 to MX-6 respectively. Their struc-
tures were elucidated by electrospray ionization mass 
spectrometry (ESI-MS), ESI-MS/MS and nuclear mag-
netic resonance (NMR) spectroscopic analysis.
Sansamycin MX-1, MX-2, MX-4 and MX-6 have 
molecular weights of 700, 863, 847 and 831, respectively. 
The ESI-MS/MS results of them (Fig. 4) showed the same 
fragment patterns with sansanmycin A. All of these four 
compounds showed the same diagnostic fragment with 
sansanmycin A, m/z 701, corresponding to the loss of the 
N-terminal amino acid (AA1), suggesting they varied at 
the N-terminal amino acid. In support of this hypothe-
sis, the 1H NMR data for MX-1 (Fig. 5a; Additional file 1: 
Table S1), MX-2 (Additional file 1: Table S2, Figure S4), 
MX-4 (Additional file 1: Table S3, Figure S6) and MX-6 
(Additional file 1: Table S4, Figure S8) proved to be very 
similar to that of sansanmycin A, with differences limited 
to replacement of the N-terminal m-Tyr in sansanmy-
cin A [δ 7.23 (t, 1H), 6.78 (d, 1H), 6.75 (d, 1H), 6.72 (s, 
1H), 4.04 (m, 1H), 2.51 (m, 1H), 2.89 (m, 1H)] [1] with a 
hydrogen in MX-1 (δ 10.78), a tyrosine (Tyr) in MX-2 [δ 
7.51 (d, 2H), 6.97 (d, 2H), 4.15 (m, 1H), 3.08 (m, 1H), 2.97 
(dd, 1H)], a Phe in MX-4 [δ 7.34 (m, 2H) 7.15 (m, 2H), 
7.27 (m, 1H), 3.92 (m, 1H), 2.73 (m, 1H), 2.86 (m, 1H)] 
and a methionine (Met) in MX-6 [δ 4.31 (m, 1H), 2.47 (m, 
1H), 2.37 (m, 1H), 1.99 (s, 3H), 1.81 (m, 1H)]. Interpreta-
tion of the 13C (Fig.  5b; Additional file  1: Figure S5, S7, 
S9) and 2D NMR data (Fig. 5c; Additional file 1: Figures 
S1–S3) also confirmed these proposed structures.
MX-3 has a molecular weight of 824, 16 mass units 
smaller than that of sansanmycin H [25], attributed to 
the loss of an oxygen atom. Furthermore, the ESI-MS/
MS spectrum of MX-3 also showed the same diagnostic 
fragment with sansanmycin H, m/z 678 for the loss of 
the N-terminal m-Tyr, which suggested that the m-Tyr in 
sansanmycin H was replaced by a Phe in MX-3. Compar-
ison with that of sansanmycin H, the 1H NMR spectrum 
of MX-3 (Additional file 1: Figure S10) showed a different 
aromatic pattern from sansanmycin H, with a Phe [δ 7.15 
(m, 2H), 7.15 (m, 2H), 7.27 (m, 1H)] instead of m-Tyr [δ 
7.23 (t, 1H), 6.78 (d, 1H), 6.75 (d, 1H), 6.72 (s, 1H)] [25].
MX-5 has a molecular weight of 863, 16 mass units 
greater than MX-4, corresponding to an extra oxygen 
atom. Comparison with that of MX-4, the 1H NMR spec-
trum of MX-5 (Additional file  1: Figure S11) showed a 
downfield shifted methyl proton signal [from δ 2.01 (−
SCH3) to 2.46 (−SOCH3)], which hinted the oxidation of 
MX-4 to MX-5. The ESI-MS/MS analysis (Fig. 4) further 
confirmed this hypothesis.
The obtained six compounds MX-1–6 were new mem-
bers of sansanmycin family. Compared with SS-A, MX-1, 
short of the N-terminal m-Tyr, bears a tri-pseudopeptide 
backbone that was found in the family of UPAs for the 
first time. It is the accumulated precursor when there 
is no m-Tyr present in SS/XKO, which is also the obvi-
ous evidence that SsaX catalyzes the biosynthesis of m-
Tyr. The other five compounds were different from the 
Fig. 3 Effects of supplying SS/XKO with meta-tyrosine (m-Tyr), 
tyrosine (Tyr) and phenylalanine (Phe). a HPLC analysis of the culture 
broth of different supplementations. The final concentration of each 
exogenous substrate was 3 mM. b Antibacterial activity analysis of 
the culture broth of different supplementations
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known sansanmycins by the virtue of bearing Tyr, Phe 
and Met at the N-terminus, which were firstly reported 
in the family of UPAs. The presence of the new sansan-
mycin analogues with various N-terminal amino acids 
hinted that the NRPS responsible for the incorporation of 
the N-terminal amino acid into the tetra-pseudopeptide 
backbone has moderate substrate promiscuity, suggesting 
that certain amounts of sansanmycin analogues might 
be able to be generated by mutational biosynthesis using 
ssaX deletion mutant SS/XKO.
Generation of structurally diverse sansanmycin analogues 
using ssaX deletion mutant
Initially twenty proteinogenic amino acids including Phe, 
Tyr and Met were used to probe the feasibility of muta-
synthesis. The production of sansanmycin MX-2 which 
bears Tyr as its N-terminus was nearly doubled when fed 
SS/XKO with Tyr (3 mM) (Fig. 3). Similarly, the produc-
tion of sansanmycin MX-4 which bears Phe as its N-ter-
minus was increased to two to three times when fed with 
Phe (3 mM) (Fig. 3). But the HPLC profile of the fermen-
tation broth of ssaX deletion mutant fed with Met, as well 
as other proteinogenic amino acids (3 mM) had no obvi-
ous changes (data not shown). This may be explained by 
the substrate preference of the NRPS, which preferred 
to select Phe or Tyr rather than any other proteinogenic 
amino acids. This result is consistent with the produc-
tion level of sansanmycin analogues in SS/XKO. The 
improved production of sansanmycin MX-2 and MX-4 
by feeding substrates Phe and Tyr suggested that muta-
synthesis might be suitable to produce sansanmycin ana-
logues with alternate N-terminal substrate.
Incorporation of halogens into the molecules might 
exert a significant effect on their physicochemical prop-
erties of the products [26, 27]. Halogenated Phe had been 
fed to get sansanmycin analogues in the wild type strain 
by Xie et al. and they were preferably incorporated at the 
C-terminus (AA4) [28]. In order to incorporate halogen-
ated Phe into sansanmycin analogues at the N-terminus 
efficiently, the ssaX deletion mutant SS/XKO was evalu-
ated. Some new sansanmycin analogues were produced 
by SS/XKO and their structures were determined by ESI-
MS/MS. These sansanmycin analogues may be divided 
into three main groups (Fig. 6a). Compounds in the first 
Fig. 4 (+)-ESI-MS/MS data and structures of ten new sansanmycin analogues
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and second groups were with halogenated Phe incor-
porated into the N-terminus (e.g., compounds 1 and 2) 
or both the N-terminus and the C-terminus (e.g., com-
pounds 3 and 4) respectively. The third group was with 
halogenated Phe incorporated into the C-terminus and 
with Phe at the N-terminus instead of m-Tyr (e.g., com-
pounds 5 and 6). What’s more, the production level of 
the analogues with halogenated Phe at the N-terminus 
was increased remarkably compared with the wild type 
strain with the same growth curves. For example, when 
fed with 2-chloro- and 2-bromophenylalanines (3  mM), 
the production level of compound 1 and 2 was 11- and 
16-fold higher in SS/XKO respectively compared with 
the wild type strain (Fig. 6b). Similarly, compound 3 and 
4 were increased 10- and 13-fold respectively (Fig. 6b). In 
a word, the ssaX deletion mutant was a better host to get 
sansanmycin analogues with N-terminus substitution, for 
its absence of the endogenous optimal substrate m-Tyr.
Motivated by the results of above feeding experiments 
and in order to expand the diversity of sansanmycins, 
more than 20 commercially available non-proteinogenic 
amino acid analogues were fed to SS/XKO (3  mM), 
including α-amino acids and β-amino acids with diverse 
side chains, such as aliphatic groups, substituted aro-
matic phenyl groups, as well as aromatic and nonaro-
matic heterocyclic groups (Fig.  7). The results showed 
that β-amino acids detected here couldn’t be incorpo-
rated into the peptidyl chain of sansanmycins. When 
feeding methyl substituted phenylalanines, the major 
products were the C-terminal derivatives with Phe at the 
N-terminus. When supplemented with para-amino-phe-
nylalanine, two products with the fed precursor incor-
porated at the N- (MX-9) and the C-terminus (MX-10) 
respectively were obtained. Unexpectedly, two aromatic 
heterocyclic α-amino acids, 2-furylalanine and 2-thie-
nylalanine, can be incorporated into the N-terminus to 
produce corresponding derivatives MX-7 and MX-8, 
respectively. The structures of MX-7–10 were determined 
by ESI-MS/MS (Fig. 4). MX-7, MX-8 and MX-9 showed 
the expected molecular weights and the same diagnostic 
fragment with sansanmycin A, m/z 701 for the loss of the 
N-terminal amino acid, suggesting the precursors added 
were incorporated into the N-terminus (Fig.  4). MX-10 
displayed the same fragment with MX-4, m/z 644 corre-
sponding to the loss of the C-terminal amino acid, which 
suggested the p-amino-phenylalanine administrated was 
incorporated into the C-terminus (Fig. 4).
The yield of each sansanmycin derivative produced 
by mutasynthesis was estimated by the peak areas from 
HPLC (Table  1). The production level of sansanmycin 
MX-4 in SS/XKO without supplementation was consid-
ered as 100 %. When fed with m-Tyr, production of san-
sanmycin A was the highest. Surprisingly, the production 
level of MX-7 bearing 2-furylalanine was much higher 
than that of MX-2 bearing Tyr. All of these results sug-
gested that other unnatural substrates might be accept-
able for the mutant strain, especially aromatic α-amino 
acids.
Antibacterial activity and stability of novel sansanmycin 
analogues
The obtained sansanmycin analogues MX-1–10 were 
tested for their antibacterial activity against different 
bacteria including gram-negative bacteria, gram-positive 
bacteria as well as M. tuberculosis H37Rv and clinically 
Fig. 5 Structural determination of sansanmycin MX-1. a 1H NMR 
spectrum of sansanmycin MX-1 (600 MHz, DMSO-d6) b 
13C NMR 
spectrum of sansanmycin MX-1 (150 MHz, DMSO-d6) c Selected 2D 
NMR correlations for sansanmycin MX-1
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Fig. 6 The production of novel sansanmycin analogues. a The structures of novel compounds produced by ssaX deletion mutant SS/XKO fed with 
halogenated Phe. The final concentration of each exogenous substrate was 3 mM. The blue labeled parts represent the halogenated Phe incor-
porated into N- and/or C-terminus. b The relative production level of novel sansanmycin derivatives 1–4 in different strains. Chloramphenicol was 
added to the cultures as an extra standard
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isolated MDR and XDR M. tuberculosis strains (Table 2). 
As expected, all the tested compounds (except MX-3) 
displayed different degrees of activity against E. coli 
ΔtolC mutant strain, which was consistent with previous 
results that UPAs can be exported by the AcrAB-TolC 
efflux system in E. coli [29]. Among them, sansanmycin 
MX-2 and MX-6 remained potency against P. aeruginosa 
equivalent to sansanmycin A. Interestingly, compound 
MX-6 exhibited antibacterial activity against gram-pos-
itive B. subtilis, which was not found in natural UPAs. 
Sansanmycin MX-1, MX-2, MX-4, MX-6 and MX-7 
showed potency against M. tuberculosis H37Rv compara-
ble to sansanmycin A. More noticeably, these tested com-
pounds exhibited equivalent potency against clinically 
isolated MDR and XDR strains. These results maybe lie in 
the fact that the target of UPAs is clinically unexploited.
During the early stage of drug development of sansan-
mycin A, we found that the structure of sansanmycin 
A was not stable at room temperature (Fig. 8a). As it is 
easier to get enough amount of sansanmycin MX-2 and 
MX-4, the stability test of sansanmycin A, MX-2 and 
MX-4 was performed in KH2PO4 buffer (pH 6.0) at room 
temperature. Under this condition, sansanmycin MX-2 
and MX-4 kept mostly unchanged after 6 days of incuba-
tion whereas less than 10 % sansanmycin A was remained 
(Fig.  8b), which suggested that sansanmycin MX-2 and 
MX-4 are more stable than sansanmycin A.
Discussion
During the past decade, considerable efforts have 
been made to exploit new UPA derivatives. Seventeen 
Fig. 7 Structures of the commercially available non-proteinogenic amino acids fed to SS/XKO. Blue labeled substrates represent the non-proteino-
genic amino acids successfully incorporated into the N-terminus. The final concentration of each exogenous substrate was 3 mM
Table 1 Comparison of  the relatively production level 
of sansanmycin analogues in ssaX deletion mutant SS/XKO




─ sansanmycin MX-4 100
m-Tyr sansanmycin A ~350
Phe sansanmycin MX-4 ~280
2-Cl/Br-Phe compound 1, 2 240–270
2-Furyl-Ala sansanmycin MX-7 ~240
Tyr sansanmycin MX-2 ~80
2-Thienyl-Ala sansanmycin MX-8 ~35
4-NH2-Phe sansanmycin MX-9 ~30
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sansanmycin analogues were semi-synthesized with san-
sanmycin A as the starting material, but most of them 
exhibited less anti-mycobacterial activity in comparison 
with parent natural product [30]. Strategy of precursor-
directed biosynthesis was employed to get pacidamycin 
analogues with modified C-terminal amino acid through 
feeding Trp derivatives [26]. The same strategy was also 
applied to sansanmycin-producing strain, resulting san-
sanmycin analogues with the C-terminus substituted by 
Phe derivatives [28]. Although some UPA analogues were 
produced, few of them had significantly improved anti-
bacterial activity and/or physicochemical property. In the 
past 5  years, the biosynthetic pathways have been stud-
ied extensively at the genetic, enzymatic and regulatory 
levels [9–13], and bioengineering approaches are avail-
able to be used in producing novel UPA derivatives. In 
this work, mutational biosynthesis is employed by block-
ing the biosynthesis of m-Tyr and then feeding variety 
of alternative substrates to produce novel sansanmycin 
derivatives. This strategy is efficient to obtain novel san-
sanmycin analogues, creating a great structural diversity 
at the N-terminus.
In most of the reported UPAs, the N-terminus of the 
tetra-pseudopeptide (AA1) was occupied by m-Tyr 
and its related bicyclic acids, except that pacidamy-
cin D and S have an Ala at the N-terminus (Fig. 1). Two 
NRPSs responsible for selection of amino acid to incor-
porate into the N-terminus of pacidamycin have been 
reported. PacU was demonstrated to specifically activate 
Ala [5], and PacW was identified to activate m-Tyr [12]. 
In sansanmycin-producing strain, there are also two 
homologues of PacU, SsaU and SsaW, existed in sansan-
mycin biosynthetic gene cluster [11], but their amino 
acid sequences were almost exactly the same, with only 
one alteration of Lys to Arg [11]. Though they exhibited 
high overall homology with both PacU and PacW, the 
main residues in the binding pocket (specificity-confer-
ring code) in the adenylation (A) domain [31, 32] were 
same with PacW but different from PacU. This is consist-
ent with the fact that m-Tyr is the optimum substrate for 
the production of sansanmycin A in the wild type strain, 
and all the natural sansanmycin derivatives have m-Tyr 
and its related bicyclic acids at the N-terminus. When 
the biosynthesis of m-Tyr is blocked, Phe, Tyr, and small 
amount of Met may incorporate into the polypeptide 
of sansanmycin in ssaX deletion mutant, showing the 
potential of this mutant as a cell factory to expand the 
chemical diversity of AA1.
Various substrates including Phe, Tyr, halogenated Phe 
and other non-proteinogenic amino acids were fed to 
the ssaX deletion mutant and about 20 novel sansanmy-
cin analogues with different N-termini were produced 
according to the substrate promiscuity of the A domain 
of SsaU and SsaW. Ten of these compounds were puri-
fied and structurally determined by ESI-MS, ESI-MS/
MS (Fig. 4) and NMR. According to the production level 
of the compounds in ssaX deletion mutant fed with cor-
responding substrate (Table  1), the preference of the A 
Table 2 Activities of sansanmycin analogues
M. tuberculosis H37Rv, standard and susceptible strain. FJ05189, FJ05120 and FJ05195 are clinical isolates of M. tuberculosis. FJ05189 and FJ05120, MDR strains, resistant 




E. coli ΔtolC P. aeruginosa 11 B. subtilis CMCC (B) 63501 M. tuberculosis
H37Rv FJ05189 FJ05120 FJ05195
MX-1 32 >128 >128 16 8 8 8
MX-2 2 32 >128 16 16 8 8
MX-3 >128 >128 64
MX-4 8 64 >128 8 16 8 16
MX-5 8 >128 >128
MX-6 4 32 16 8 8 8 8
MX-7 8 128 >128 16 8 8 16
MX-8 8 128 >128
MX-9 16 128 >128
MX-10 64 >128 >128
A 2 16 >128 16 16 16 8
Streptomycin 16 4 2 0.25 <0.06 <0.06 >128
Isoniazid 0.125 8 16 >128
Rifampicin <0.06 4 >128 >128
Ethambutol 0.5 2 0.5 >128
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domain in charge of activating the sansanmycin N-ter-
minal amino acid is m-Tyr  >  Phe  ≥  ortho-halogenated 
phenylalanines  ≥  2-furylalanine  >  Tyr  >  2-thienylala-
nine ≥ p-amino-phenylalanine > Met. Out of our expec-
tation, 2-furylalanine and 2-thienylalanine could be 
incorporated into the sansanmycin, suggesting the diver-
sity of AA1 might be worth to explore further by trying 
more structurally diverse substrates. The compounds 
produced by mutasynthesis in this study retained the 
anti-TB activity of sansanmycin A in  vitro, and more 
encouragingly, they showed similar activity to MDR and 
even XDR strains isolated from patients. Meanwhile, 
the stability of MX-2 and MX-4 was demonstrated to be 
greatly improved compared to sansanmycin A.
From the result of previous researches on the UPA 
derivatives of the wild type strains [8, 25] or by precur-
sor-directed biosynthesis [26, 28], the A domain respon-
sible for activating the C-terminal amino acid (AA4) has 
relatively high substrate promiscuity from Trp, Tyr to 
Phe and substituted Phe and Trp. On the other hand, 
the amino acid at the position of AA3 also can vary from 
Met and Ala [8] to Leu and Phe in sansanmycins [25, 33]. 
Now, together with the diversity at AA1 produced in this 
study, the combination of the variations in these three 
parts of the polypeptide backbone could be potentially 
expected that hundreds of new sansanmycin analogues 
might be obtained. Recently, crystal structure of Aquifex 
aeolicus MraY has been published [34], and the residues 
(Asp117, Asp118, Asp265, and His324) important for the 
activity of MraY in the active site have been elucidated 
[34]. The structural information of MraY from A. aeolicus 
sets foundations for homologous modeling of MraY from 
M. tuberculosis [34, 35], which will facilitate the study on 
structure activity relationship (SAR) of novel chemically 
diverse UPA derivatives obtained by further rationale 
genetic engineering manipulation.
Conclusion
It is demonstrated that SsaX is responsible for the bio-
synthesis of m-Tyr in  vivo by gene deletion and com-
plementation and the sansanmycin production could be 
increased through the overexpression of ssaX. Six new 
sansanmycin analogues were purified and characterized 
in ssaX deletion mutant, indicating the substrate flexibil-
ity of the responsible NRPS. The diversity of sansanmycin 
was further expanded by mutasynthesis, in which dif-
ferent types of substrates were fed to the culture of ssaX 
deletion mutant. Totally ten compounds were purified, 
structurally identified and firstly reported. Five of them 
displayed anti-mycobacterial activity comparable to san-
sanmycin A and especially, they are active to MDR and 
even XDR M. tuberculosis clinical strains. In addition, 
sansanmycin MX-2 and MX-4 displayed significantly 
improved stability than sansanmycin A. These improved 
properties may promote the novel anti-TB drug investi-
gation targeting a clinically unexploited target MraY.
Fig. 8 Stability of sansanmycin A, MX-2 and MX-4. a HPLC analysis of 
sansanmycin A at indicated days in KH2PO4 buffer (pH 6.0) at room 
temperature. b The changes of the level of sansanmycin A, MX-2 and 
MX-4 over time. All samples were analyzed by HPLC and quantified 
according to the areas of peaks. blue line, sansanmycin MX-2; red line, 
sansanmycin MX-4; green line, sansanmycin A
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Methods
Strains, plasmids and growth conditions
The wild-type Streptomyces sp. SS strain, obtained 
from China Pharmaceutical Culture Collection (CPCC 
200442), was used as a host strain for the propagation 
and disruption of genes, as described previously [11]. 
Streptomyces sp. SS and its derivatives were grown at 
28 °C on solid S5 medium [36] for sporulation and in the 
liquid fermentation medium [1] for the production of 
sansanmycins. Mannitol soya flour (MS) agar [37] and 
liquid phage medium [38] were used for conjugation and 
isolation of genomic DNA respectively. Escherichia coli 
DH5α was used as a host for general cloning experiments 
[39]. E. coli ET12567/pUZ8002 [40] was used for conju-
gal transfer according to the established protocol [37]. E. 
coli BW25113/pIJ790 was used as the host for Red/ET-
mediated recombination [21]. E. coli DH5α containing 
the temperature sensitive FLP recombination plasmid 
BT340 was used as the host to remove the central part of 
the disruption cassette [21]. E. coli DH5α and ET12567/
pUZ8002 were incubated in Luria–Bertani medium (LB) 
[39] at 37 °C. E. coli BW25113/pIJ790 and DH5α/BT340 
were grown at 30 °C in LB medium. P. aeruginosa 11, the 
indicator strain for the antibacterial bioassay of culture 
broth of different Streptomyces sp. SS strains [6], was 
grown on F403 agar [36]. E. coli ΔtolC mutant, P. aerugi-
nosa 11, Bacillus subtilis CMCC (B) 63501, M. tubercu-
losis H37Rv and clinically isolated strains were used for 
testing antimicrobial activity for the compounds. When 
required, strains were incubated with apramycin (Am, 
50  μg/ml), ampicillin (Amp, 100  μg/ml), spectinomycin 
(Spec, 50  μg/ml), kanamycin (Km, 50  μg/ml) and chlo-
ramphenicol (Cm, 30 μg/ml). All the strains and plasmids 
used in this study are listed in Table 3.
Construction and complementation of Streptomyces sp. SS 
ssaX mutant
The ssaX in-frame deletion mutant SS/XKO was con-
structed by the λ-RED mediated PCR targeting method 
[21], using cosmid 13R-1 [11] covering ssaM–ssaV 
of sansanmycin biosynthetic gene cluster. In order 
to disrupt ssaX through homologous recombination, 
the minimal replicon of SCP2* of 13R-1 was firstly 
replaced by ampicillin resistance marker bla, resulting 
13R-1-SCP2KO. Then, a streptomycin resistance cas-
sette (aadA gene) was amplified with primers PT-X-1 
(5′-GCGGGAGGCCCCGCTGAACAGGGCCGCGAT 
GCTGTCGTCATTCCGGGGATCCGTCGACC-3′) 
and PT-X-2 (5′-GTCACCGACACCGCCTATGAGAA 
GCGCCGCGAGGAGATCTGTAGGCTGGAGCT 
GCTTC-3′) including two 39-nt homologous extensions 
to sequences up- and downstream of the target ssaX 
gene. The cassette was introduced into E. coli BW25113/
pIJ790 to substitute ssaX on cosmid 13R-1-SCP2KO. The 
streptomycin resistance cassette on the correct recombi-
nant cosmid was removed by FLP-recombinase in E. coli 
DH5α/BT340. The mutant cosmid 13R-1-SCP2KO-XKO 
was introduced into E. coli ET12567/pUZ8002 and then 
transferred into Streptomyces sp. SS by conjugation. Dou-
ble-crossover exconjugants (Ams) were selected on MS 
agar with and without Am and confirmed by PCR using 
primers PT-X-7 (5′-TGAAGCCCGCCGCCTTTC-3′) 
and PT-X-8 (5′-TCTGCCTTCCGCCTGACCAT-3′) 
and southern blot hybridization using DIG Prime DNA 
Labeling and Detection Starter Kit I (for color detec-
tion with NBT/BCIP, Roche). The genomic DNAs were 
digested with BamHI and hybridized with specific probes 
of ssaX deleted fragment amplified with primers SB-X-1 
(5′-CTCGACCTCGTTCATGGAGT-3′) and SB-X-2 
(5′-AGTACGTCGACTGGGAGCAC-3′) and the frag-
ment downstream of ssaX amplified with primers SB-X-3 
(5′-AGAAACCACGATGCGAAATC-3′) and SB-X-4 
(5′-TGGATTTTTCGCTTCAAACC-3′) respectively. 
The resulted ssaX deletion mutant was designated SS/
XKO.
For complementation analysis, complete ssaX cod-
ing region was amplified using primers pL-ssaX-F 
(5′-CGCATATGCAAGGGCATCGCGAC-3′) and 
pL-ssaX-R (5′-ATAGGATCCTCAGCGCCGGGTG 
CC-3′), and then cloned into the NdeI and BamHI sites 
of a pSET152-derived expression plasmid, pL646 [23], 
under the control of a strong constitutive promoter 
ermE*p. The resulted expression vector pL-ssaX was 
transferred into SS/XKO and Streptomyces sp. SS by con-
jugation to give the complementation strain and ssaX 
overexpression strain respectively. The plasmid pSET152 
[22] was transferred to SS/XKO and the wild type strain 
respectively as controls.
Analysis of sansanmycin production
Fermentation, isolation, and high-pressure liquid chro-
matography (HPLC) analysis of sansanmycins were car-
ried out as described previously [1, 25]. In brief, pieces 
of well-grown agar cultures of different strains were 
firstly inoculated in fermentation medium and cultured 
at 28 °C for 48 h at 200 rpm. The obtained seed cultures 
were trans-inoculated into three parallel 100 ml fermen-
tation medium by 5 % inoculation and grown at 28 °C for 
5  days at 200  rpm. In the feeding test, each exogenous 
substrate was added to the fermentation medium to the 
final concentration of 3  mM. At indicated time points, 
five-milliliter cell cultures were collected by centrifu-
gation and dried at 60  °C to constant weight for moni-
toring the growth curve. The obtained supernatants 
were analyzed for antibacterial activity and production 
of sansanmycins by bioassay and HPLC. Antibacterial 
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activity was measured by cylinder plate method using 
P. aeruginosa 11. For analyzing the expected analogues, 
the supernatant of fermentation broth was enriched by 
Sep-Pak C18 Classic Cartridge (Waters Associates, Mil-
ford, MA, USA), eluted with 60  % methanol solution. 
The effluent was subjected to HPLC on an XBridge™ C18 
column (4.6 × 150 mm, 3.5 μm, Waters, Dublin, Ireland) 
maintained at 40 °C, with a gradient of 80:20 0.1 % (w/v) 
(NH4)2CO3-MeOH to 40:60 in 40  min as mobile phase 
at a flow rate of 1  ml/min. Absorbance was monitored 
at 254  nm. For the analysis of sansanmycin MX-3 and 
MX-6, the mobile phase was changed to 10:90 MeOH-
H2O (pH adjusted to 12.0 with NH3·H2O) in 40 min.
Purification of sansanmycin analogues
Isolation and purification of sansanmycin analogues 
was performed following the method of Xie et  al. [25] 
with some modifications. Fifty liters of fermentation 
supernatant was obtained by centrifugation and then 
applied on a column of macroporous absorbant resin 
4006. The active materials were eluted with 30  % aque-
ous acetone. Then the effluent was applied on Toyopearl 
DEAE-Sephadex A25 eluted with Tris-HCl (20 mM, pH 
8.5) plus NaCl and monitored by HPLC-UV. The concen-
tration of NaCl was adjusted with different compounds 
from 0.01 to 0.05 M. The effluent containing target com-
pounds was collected and further purified by preparative 
HPLC (YMC-Pack ODS-A 5 μm, 250 × 20 mm column, 
0.1 % (w/v) (NH4)2CO3-MeOH; flow rate, 5 ml/min; UV 
detection at 254 nm and oven temperature at 40 °C). The 
ratio of 0.1 % (w/v) (NH4)2CO3 and MeOH was depend-
ent on different compounds. The structures of obtained 
compounds were determined using ESI-MS and ESI-MS/
MS (ThermoFisher LTQ Orbitrap XL mass spectrometer) 
as well as NMR [Varian Mercury 600 spectrometers, in 
dimethyl sulfoxide (DMSO)-d6].
Antibacterial assay
The minimum inhibitory concentrations (MICs) for M. 
tuberculosis strains were determined by the microplate 
Table 3 Strains and plasmids used in this study
Ampr ampicillin resistance, Amr apramycin resistance, Km kanamycin resistance, Cmr chloramphenicol resistance, Specr spectinomycin resistance
Strains/plasmids Relevant characteristics Reference
Strains
Streptomyces sp. SS Wild-type strain (sansanmycin-producing strain), CPCC 200442 [1]
 SS/XKO Mutant of Streptomyces sp. SS with the in-frame deletion of ssaX This study
 SS/XKO/pL-ssaX SS/XKO with the expression vector pL-ssaX, Amr This study
 SS/pL-ssaX Streptomyces sp. SS with the expression vector pL-ssaX, Amr This study
Escherichia coli
 DH5α General cloning host [39]
 ET12567/pUZ8002 Donor strain for intergeneric conjugation between E. coli and Streptomyces, Cmr, Kmr [40]
 BW25113/pIJ790 Strain for RED/ET-mediated recombination, Cmr [21]
 ΔtolC mutant Strain for testing antimicrobial activity [44]
Pseudomonas aeruginosa 11 Strain for sansanmycin bioassays [6]
Bacillus subtilis CMCC (B) 63501 Strain for testing antimicrobial activity
Mycobacterium tuberculosis Strain for testing antimicrobial activity
 H37Rv Standard strain, susceptible to isoniazid and rifampicin
 FJ05189 Clinically isolated multi-drug-resistant strain, resistant to isoniazid and rifampicin
 FJ05120 Clinically isolated multi-drug-resistant strain, resistant to isoniazid and rifampicin
 FJ05195 Clinically isolated extensive-drug-resistant strain, resistant to isoniazid, rifampicin, ethambutol, streptomy-
cin, kanamycin and ofloxacin
Plasmids
13R-1 Cosmid based on vector pOJ446, containing the majority of sansanmycin biosynthetic gene  
cluster ssaM–ssaV including ssaX
[11]
13R-1-SCP2KO Cosmid 13R-1with the minimal replicon of SCP2* replaced by ampicillin resistance marker bla,  
Ampr, Amr
This study
13R-1-SCP2KO-XKO Cosmid 13R-1-SCP2KO with the in-frame deletion of ssaX, Ampr, Amr This study
pIJ779 Vector used as the template for amplifying aadA cassette, Specr [21]
pSET152 Streptomyces integrative vector, Amr [22]
pL646 pSET152 derivative containing the constitutive promoter ermE*p, Amr [36]
pL-ssaX pL646 derivative plasmid containing 843 bp complete coding region of ssaX This study
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Alamar blue assay (MABA) [41]. All M. tuberculosis 
strains were grown on Middlebrook 7H9 medium sup-
plemented with 0.2 % (v/v) glycerol and 10 % (v/v) OADC 
(oleic acid, albumin, dextrose, catalase) until the mid-log 
phase of growth at 37  °C. The final suspension of bacte-
ria cells were diluted in Middlebrook 7H9 medium to 
106  cfu/ml. Initial compound dilutions were prepared in 
DMSO, and subsequent twofold dilutions were performed 
in 100 μl of 7H9 (no Tween 80) in the microplates. Then, 
the MIC was measured in sterile 96-well plates with 100 μl 
of the bacterial suspension and 100 μl compound dilution 
per well. The MIC was defined as the lowest concentra-
tion of drug that prevented the color change of Alamar 
blue reagent from blue to pink. Rifampicin, isoniazid, eth-
ambutol and streptomycin were used as controls.
The MICs for other bacterial strains were determined by 
a microdilution test following recommendations from the 
Clinical and Laboratory Standards Institute (CLSI, formerly 
NCCLS) [42]. The bacterial strains were grown on Muel-
ler–Hinton broth (MHB) [43], and the final suspension 
of bacteria (in MHB medium) was adjusted to 106  cells/
ml. The dilutions of tested compounds were performed 
as method above with MHB medium instead. Then serial 
dilutions (100 μl) were transferred to a 96-well plate in trip-
licate, and 100  μl of the bacterial suspension was added 
to each well. After incubation at 37  °C for 24 h, the MIC 
was defined as the lowest concentration that inhibited the 
growth of the tested organism detected by visual observa-
tion. Streptomycin was used as the positive control.
Stability determination of sansanmycin analogues
To dissect the stability of sansanmycin A and other san-
sanmycin analogues, compounds were dissolved in 
0.05 M KH2PO4 buffer (pH adjusted to 6.0 with NaOH). 
All samples were incubated at 25 °C for 9 days. Each sam-
ple has three parallel repeats. Residual analogues were 
analyzed by HPLC and quantified by the peak areas.
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